Exchange: NASDAQ·Updated 07:00 AM EDT
MNKD logo

MNKDMannkind Corp

$4.00
$0.02
(0.50%)
Pre-Market
Prev Close $3.98
EarningsAug 5
Mkt Cap$1.25B
Vol1,394.00
News
all
press releases
What This MannKind Filing Reveals About Three Years of Underperformance
Key PointsThis MannKind insider filing details the disposition of 46,795 shares...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
Key PointsThe transactions involved 76,880 shares with a total value of about $313,000, based on a weighted average execution price of $4.07 per share...
Nasdaq News: Markets
News Placeholder
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million
Key PointsDavid Thomson disposed of 123,000 shares at $4.08 per share, representing a total transaction value of about $500,000...
Nasdaq News: Markets
News Placeholder
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk
Key PointsThis filing reported an insider's total disposition of 65,808 shares for an estimated value of $269,000 based on the July 15, 2026 market close...
Nasdaq News: Markets
News Placeholder
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?
Key PointsThe disposition involved ~363,000 shares valued at ~$1.5 million as of the July 15, 2026 transaction date...
Nasdaq News: Markets
News Placeholder
Jim Cramer Says He Blessed MannKind as a Speculation Only
Jim Cramer Says He Blessed MannKind as a Speculation Only...
Yahoo! Finance: News
News Placeholder
S&P 500 Jumps For Ninth Week, Longest Since 2023 With DELL Leading Nasdaq To Record Highs, While Positive US-Iran Ceasefire Bets Aid Dow — UMG, COIN, MNKD, ASTC, ASTS In Focus
President Donald Trump said he was ready to make a “final determination” on a preliminary agreement to extend the ceasefire.
Stocktwits
News Placeholder
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children
U.S. Food and Drug Administration (FDA) has approved Afrezza Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.
Stocktwits
News Placeholder
MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment
The FDA set a PDUFA action date for MannKind’s Afrezza inhaled insulin therapy for children and adolescents with diabetes.
Stocktwits
News Placeholder
UTHR Holds As Tyvaso Shows 33% Lower Worsening Risk In Rare Lung Scarring Disease
UTHR Holds As Tyvaso Shows 33% Lower Worsening Risk In Rare Lung Scarring Disease
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.